Learn about immunotherapy and checkpoint inhibitor drugs in this comprehensive physician grand rounds presentation. Explore the biology of immune checkpoints, PD1 inhibitors for melanoma treatment, and combination therapies using CTLA4 and PD1 blockade. Examine adjuvant checkpoint inhibitor treatments for melanoma, including ipilimumab and PD1 inhibitors. Discover the use of checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) and as adjuvant therapy after chemoradiotherapy for stage III NSCLC. Gain insights into predictors of response and strategies for managing toxicity associated with these treatments. This 52-minute lecture, delivered by Dr. Joseph Merchant from McFarland Clinic's Hematology/Oncology department, provides a comprehensive overview of targeted immunotherapy approaches in cancer treatment.
Immunotherapy - Checkpoint Inhibitor, Targeted Immunotherapy Drugs
Mary Greeley Medical Center via YouTube
Overview
Syllabus
Intro
Case Presentation
Immune Checkpoints --Biology
PD1 Inhibitor for Melanoma
PD1 Trials in Melanoma
Combination of CTLA4 and PD1 blockade in Melanoma: Checkmate 067 Trial
Adjuvant Checkpoint Inhibitor Treatment --Melanoma Adjuvant Ipilimumab was studied in comparison to placebo in treatment of patients who had undergone complete resection of stage lIl Melanoma at a dose of 10 mg.kg every 3 weeks X 4 followed by every 3 months X 3 years. - At 5.3 years follow-up the recurrence free survival was 40.8% in Ipilimumab group compared to 30.3% in placebo
Adjuvant PD1 Inhibitors for Stage III Melanoma
Checkpoint Inhibitors in Advanced NSCLC
Predictors of Response
(PACIFIC Trial) Checkpoint Inhibitor as Adjuvant Therapy after Chemo- Radiotherapy for Stage III NSCLC
Management of Toxicity
Taught by
Mary Greeley Medical Center
